Muscle Preservation in Healthcare: Sarcopenia & Muscle Loss 2026

Executive Brief

Preserving lean tissue is becoming a primary treatment objective across modern care pathways.

As aging populations, GLP-1 adoption, cancer cachexia, and post-surgical recovery challenges intensify, muscle preservation is moving from a niche concern to a core healthcare priority.

Executive Summary

Muscle preservation has emerged as one of the most consequential challenges in modern healthcare. Once viewed primarily as a concern for athletes and the elderly, preserving skeletal muscle mass is now recognized as a critical pillar of metabolic health, longevity, post-surgical recovery, and chronic disease management.

The simultaneous rise of the global aging population and the explosive adoption of GLP-1 weight-loss medications has created an urgent demand for innovations that protect lean tissue mass across patient populations.

This article examines the most significant trends, technologies, and companies shaping muscle preservation medicine in 2026 — spanning pharmaceutical breakthroughs, regenerative biologics, wearable bioelectronics, AI-powered diagnostics, and digital therapeutics.

1. The Muscle Preservation Imperative

Sarcopenia — the progressive loss of skeletal muscle mass and strength — is now recognized as a disease by the WHO. Affecting over 50 million people globally, it increases the risk of frailty, disability, and mortality. The sarcopenia therapeutics market was valued at approximately $3.1 billion in 2024 and is projected to grow steadily through 2032.

Four major forces are driving muscle preservation into mainstream healthcare:

GLP-1 Medication Surge

Clinical trials show that 26%–40% of weight lost on drugs like semaglutide comes from lean mass, creating a large-scale risk.

Aging Demographics

The population aged 80+ is expected to triple by 2050, making muscle health central to functional independence.

Cancer & Chronic Disease

Cachexia affects 50–80% of cancer patients and contributes significantly to mortality.

Surgical Recovery

Immobility and ICU stays accelerate muscle loss, making preservation critical for recovery outcomes.

2. Pharmacological Frontiers

Blocking myostatin — a protein limiting muscle growth — remains a leading strategy. Regeneron’s trevogrumab has shown the ability to preserve lean mass when combined with semaglutide. Companies like Novartis and Keros Therapeutics are advancing similar pathways.

The BELIEVE study demonstrated that combining bimagrumab with semaglutide preserves lean mass while enhancing fat loss, driving major pharmaceutical interest.

Sarconeos (Biophytis)

Isomyosamine (TNF Pharmaceuticals)

RJx-01 (Rejuvenate Biomed)

LPCN 1148 (Lipocine)

KER-065 (Keros Therapeutics)

Companies like Immunis are developing stem cell-derived biologics targeting immune and muscle function. Others, including Turn Biotechnologies and Retro Biosciences, are exploring epigenetic reprogramming and autophagy enhancement.

3. Drug Discovery & AI Platforms

AI in healthcare market intelligence is accelerating muscle preservation research by improving target identification and development speed.

ProFuse Technology

Uses cell-based systems to identify compounds that prevent muscle loss.

AI-Driven Discovery

Platforms like ALEMBIC (Rubedo Life Sciences) and data infrastructure providers like Palantir enable faster translational research.

AI + Biology Integration

Partnerships such as Retro Biosciences with OpenAI demonstrate how AI can enhance stem cell engineering and production efficiency.

4. Wearable Technology & Real-Time Monitoring

Wearable Bioelectronics

Devices using EMG, BIA, and biosensors track muscle health in real time by measuring biomarkers like creatine kinase and IGF-1. These are increasingly used in home-based care.

Continuous Protein Biosensors

New sensors can track biomarkers like phenylalanine to monitor muscle breakdown and protein intake, offering real-time nutritional feedback.

Electrical Muscle Stimulation

EMS delivers high-intensity muscle contractions, showing significant improvements in strength and muscle thickness when combined with training.

5. Digital Therapeutics & Care Delivery

Area	Example	Role in muscle preservation
Digital Programs	Sword Health	Structured resistance-based programs supported by wearable sensors and clinical specialists.
Remote Monitoring	Smart rehabilitation devices	Real-time tracking of muscle loading and recovery progress after injury or surgery.
Telehealth & Nutrition	LifeMD, Teladoc	Integrated diagnostics, nutrition, and pharmacological care within chronic disease and weight-management programs.

6. Nutritional Science & Emerging Interventions

Nutrition remains the foundation of muscle preservation. Clinical guidelines emphasize resistance exercise and adequate protein intake, particularly leucine-rich sources.

Emerging areas include precision protein timing during GLP-1 therapy, vitamin D and omega-3 supplementation, creatine for muscle energy and anabolic signaling, and personalized nutrition using genetic insights.

Clinical foundation

Resistance exercise
Adequate protein intake
Leucine-rich nutrition
Supplement support where appropriate

7. Regulatory & Market Landscape

WHO Recognition

Sarcopenia’s classification as a disease has enabled reimbursement pathways and increased investment.

FDA Environment

While regulatory interest is growing, delays and workforce challenges have impacted approval timelines. AI-driven medical devices are expected to expand significantly.

Investment Trends

Muscle preservation is attracting strong capital inflows, with AI-driven healthcare startups raising billions and increased M&A activity across biotech and digital health.

8. Future Outlook: Technologies to Watch

Gene therapy and epigenetics aimed at restoring youthful muscle function.

3D bioprinting advances in tissue engineering for muscle regeneration.

Smart exoskeletons supporting rehabilitation and mobility.

Longevity integration placing muscle health at the center of healthspan strategies.

Muscle preservation has evolved into a central pillar of modern healthcare. In 2026, it is no longer a secondary concern but a primary treatment objective requiring proactive, multi-modal intervention across the healthcare continuum.

Conclusion

The convergence of aging populations, GLP-1 adoption, disease recognition, and innovation across pharmaceuticals, AI in healthcare and real-world data analytics , wearables, and digital health has created a dynamic and fast-growing sector focused on preserving muscle mass, recovery, and overall health.

Muscle Preservation in Healthcare

Preserving lean tissue is becoming a primary treatment objective across modern care pathways.

Executive Summary